海辰药业(300584.SZ)：2025年中报净利润为2915.77万元

Core Insights - The company reported a total revenue of 309 million yuan and a net profit attributable to shareholders of 29.16 million yuan for the first half of 2025 [1] - The operating cash flow showed a net inflow of 65.64 million yuan [1] Financial Metrics - The latest debt-to-asset ratio is 28.88%, which is an increase of 0.07 percentage points from the previous quarter [3] - The gross profit margin is 85.88%, reflecting a decrease of 0.21 percentage points compared to the last quarter [3] - The return on equity (ROE) stands at 2.80% [3] - The diluted earnings per share (EPS) is 0.24 yuan [3] - The total asset turnover ratio is 0.21 times, while the inventory turnover ratio is 0.53 times [3] Shareholder Structure - The number of shareholders is 26,000, with the top ten shareholders holding a total of 69.67 million shares, accounting for 58.06% of the total share capital [3] - The largest shareholder, Cao Yuping, holds 42.08% of the shares [3] - Other notable shareholders include Jiang Xiaoqun (9.98%) and Liu Xiaoqian (2.86%) [3]